Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE: Response to consultation
DATE: 2019-05-24
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents

CMA response:

HEALTH CANADA CONSULTATION ON REDUCING YOUTH ACCESS AND APPEAL OF VAPING PRODUCTS

[Document Image]
Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy10045

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2010-12-04

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA POLICY

Cannabis for Medical Purposes

The Canadian Medical Association (CMA), recognizes the unique requirements of those individuals suffering from terminal illness or chronic disease for which conventional therapies have not been effective and for whom cannabis is used to alleviate their symptoms. However, there is a need for more scientific and clinical evidence to support the effectiveness and safety of cannabis for medical purposes.

The CMA encourages the following recommendations:

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis, to facilitate the development of evidence-based guidelines for its use.

2. Develop regulatory guidelines for the safe and effective use of cannabis in clinical practice.

3. Promote awareness of the need for public education and patient counseling regarding the therapeutics of cannabis.

4. Support the development of appropriate research and clinical trials to evaluate the efficacy and safety of cannabis for medical purposes.

5. Advocate for public policy that recognizes the medical benefits of cannabis and supports its safe and responsible use.

6. Encourage the development of evidence-based guidelines for the use of cannabis in palliative care.

7. Support the development of appropriate regulations to ensure the safe and effective use of cannabis in clinical practice.

8. Promote awareness of the need for public education and patient counseling regarding the therapeutics of cannabis.


10. Advocate for public policy that recognizes the medical benefits of cannabis and supports its safe and responsible use.

11. Encourage the development of appropriate regulations to ensure the safe and effective use of cannabis in clinical practice.
MEDICATION USE AND SENIORS

(UPDATE 2017)

This Canadian policy is freely available to you. For more information, visit https://policybase.cma.ca/.

The Canadian Medical Association (CMA) endorses the following recommendations for the optimal use of medications by seniors:

1. **Optimal Medication Use through Comprehensive Care**
   - Comprehensive care plans should be developed for seniors, focusing on their medication use.
   - Health professionals should assess, monitor, and manage medication use comprehensively to ensure the best possible outcomes.

2. **Managing Polypharmacy**
   - Seniors taking five or more medications should be reviewed by a pharmacist or a physician to reduce unnecessary prescriptions.
   - Medication review should be ongoing, and new medications should be introduced with caution.

3. **Prescribing Education**
   - Health care providers should be educated about the importance of considering the patient's overall health when prescribing medications.
   - Patients and caregivers should be educated about the potential risks and benefits of medications.

4. **Compliance and Adherence**
   - Medication adherence programs should be developed to improve adherence rates among seniors.
   - Electronic prescribing systems can assist in tracking medication adherence.

5. **Cannabis and Seniors**
   - Seniors should be educated about the risks and benefits of cannabis use.
   - Pharmacists and physicians should be knowledgeable about cannabis and its interactions with other medications.

6. **Monitoring and Reporting**
   - Health systems should have mechanisms in place for monitoring medication use and reporting adverse drug events.
   - Seniors should be encouraged to report any adverse effects of medications.

7. **Advocacy and Support**
   - Seniors should have access to advocacy and support services to help them manage their medication use.

8. **Quality Improvement**
   - Health care systems should prioritize quality improvement initiatives focused on medication use in seniors.

This policy is intended to guide health care providers and seniors in optimizing medication use, promoting health and well-being in older adults.

CMA Policybase - Canadian Medical Association
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2012-12-08
TOPICS  Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

POLICY TYPE
Response to consultation

DATE
2019-02-20

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents